The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials
Lishen Liu, Jingqi Chen, Xiaoming Zhang, Sidong Zhu, Tianfu Dai, Qingping Wu, Yinchao Fang · 2025
Read The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials by Lishen Liu, Jingqi Chen, Xiaoming Zhang, Sidong Zhu, Tianfu Dai, Qingping Wu, Yinchao Fang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12781576.txt.
Description
Lishen Liu and co-authors pooled twenty trials to check whether the blockbuster drug tirzepatide harms heart or kidneys, in a 2025 meta-analysis. The trials covered 15,905 people with type 2 diabetes or obesity, against placebo or other treatments. Heart attacks, strokes, heart failure, kidney impairment, stones, and infections all counted as adverse events.
No significant link appeared either way: the heart event ratio sat at 0.83 and the kidney ratio at 1.22, both with wide intervals crossing safety. Subgroups by disease, dose, and comparator told the same story. Within trial horizons, the drug's powerful benefits arrive without a proven organ penalty, the authors conclude.
Catalog record
| CREATOR | Lishen Liu, Jingqi Chen, Xiaoming Zhang, Sidong Zhu, Tianfu Dai, Qingping Wu, Yinchao Fang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |